Sexual Health & Metabolic Peptides

PT-141, also known as bremelanotide, is the synthetic cyclic heptapeptide analogue of the melanocortin peptide Melanotan II (MT-II), and holds the distinction of being the only FDA-approved peptide for sexual dysfunction, specifically, hypoactive sexual desire disorder (HSDD) in premenopausal women (Vyleesi, approved 2019). Its approval represents the first neuroscience-based treatment for HSDD, working through central nervous system mechanisms rather than peripheral vascular effects, a fundamentally different approach from PDE-5 inhibitors used in men (PMID 30907540).

Bremelanotide is a melanocortin receptor agonist with activity primarily at MC1R, MC3R, and MC4R. MC4R in particular is expressed in hypothalamic and limbic brain regions involved in sexual arousal, motivation, and reward processing. Activation of MC4R in these regions increases dopaminergic and noradrenergic neurotransmission in the mesolimbic pathway, the brain's reward and motivation system, enhancing sexual desire at a central, neurobiological level. This mechanism is distinct from testosterone and estrogen, which also modulate sexual desire but through different signaling systems; from PDE-5 inhibitors, which work purely on penile/clitoral vascular smooth muscle; and from flibanserin (the first FDA-approved treatment for HSDD, a serotonin-norepinephrine modulator). The melanocortin system thus represents a third distinct neurobiological pathway to sexual desire modulation (PMID 30907540).

The pivotal clinical trials (RECONNECT studies, n=594 premenopausal women with HSDD) demonstrated that bremelanotide 1.75 mg SQ (administered 45 minutes before anticipated sexual activity, as needed) significantly increased the number of satisfying sexual events (the primary endpoint), decreased personal distress associated with low sexual desire, and improved Female Sexual Function Index scores compared to placebo. Effect sizes were statistically significant but modest in absolute terms, approximately one additional satisfying sexual event per four weeks compared to placebo in the pooled analysis. The modest absolute effect size reflects the complexity of female sexual desire as a multifactorial construct (psychological, relational, hormonal, and neurobiological factors all contribute) that no single agent can fully address.

Off-label use in men (for erectile dysfunction, particularly in PDE-5 inhibitor non-responders) is an active area of clinical practice driven by the discovery of bremelanotide's sexual effects, bremelanotide was originally being developed as a sunless tanning agent when male clinical trial participants reported spontaneous penile erections as a "side effect." Multiple small studies and clinical case series report significant erectile response to bremelanotide in men with both psychogenic and organic ED, including some PDE-5 inhibitor non-responders who respond to the central melanocortin mechanism. The combination of bremelanotide + a PDE-5 inhibitor has been used empirically for men with both central (desire) and peripheral (vascular) components of ED.